Sugi Predict

Sugi Predict / Compounds / SCHEMBL29529240

SCHEMBL29529240

SCHEMBL29529240

NS(=O)(=O)c1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 7/20 1.00
▸ CA1 P00915 6/20 1.00
▸ CA9 Q16790 5/20 1.00
▸ CDK2 P24941 1/20 0.61
▸ F2 P00734 3/20 0.56
▸ PRSS1 P07477 3/20 0.56
▸ PRSS2 P07478 3/20 0.56
▸ PRSS3 P35030 3/20 0.56
▸ HTR6 P50406 1/20 0.56
▸ LDHA P00338 1/20 0.55
▸ CA12 O43570 3/20 0.52
▸ CA4 P22748 2/20 0.52
▸ CA6 P23280 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CA5A P35218 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52
▸ CA5B Q9Y2D0 1/20 0.52
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28464 1.00 CA2 (1.00) CA2CA1CA9CDK2F2
Hydrochloric Acid SCHEMBL951327 0.98 CA2 (0.96) CA2CA1CA9CDK2F2
Benzene SCHEMBL11062753 0.98 CA2 (0.96) CA2CA1CA9CDK2F2
Hydrochloric Acid SCHEMBL8125684 0.96 CA2 (0.92) CA2CA1CA9CDK2F2
Phosphoric Acid SCHEMBL28841729 0.90 CA2 (0.81) CA2CA1CA9CDK2F2
Isothiocyanate SCHEMBL28619475 0.89 CA2 (0.79) CA2CA1CA9CDK2F2
Acetamide SCHEMBL28617889 0.89 CA2 (0.79) CA2CA1CA9CDK2F2
SCHEMBL3149642 0.88 CA2 (0.78) CA2CA1CA9CDK2F2
Pyrrolidine SCHEMBL17599458 0.86 CA1 (0.73) CA2CA1CA9CDK2F2
SCHEMBL9138970 0.85 CDK2 (0.78) CA2CA1CA9CDK2LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 — — US disclosed
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof INSTITUT CURIE (FR) 2026-01-20 — — US disclosed
US-12455285-B2 Method for detecting bacteria according to the gram signal thereof in a complex sample MAAT PHARMA (FR) 2025-10-28 — — US disclosed
US-20250281535-A1 ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF ABOLERIS PHARMA (FR) 2025-09-11 — — US disclosed
EP-4401842-B1 ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF ABOLERIS PHARMA (FR) 2025-08-27 — — EP disclosed
US-20250122300-A1 ANTI-HUMAN CD45RC ANTIBODIES AND USES THEREOF INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2025-04-17 — — US disclosed
US-12168694-B2 Anti-human CD45RC antibodies and uses thereof INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2024-12-17 — — US disclosed
EP-4401842-A1 ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF Aboleris Pharma (FR) 2024-07-24 — — EP disclosed
US-20240033366-A1 FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF INSTITUT CURIE (FR) 2024-02-01 — — US disclosed
US-20230357354-A1 CD38-BINDING CD31 PEPTIDES AND USES THEREOF ENCEFA (FR) 2023-11-09 — — US disclosed
EP-4255475-A1 FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STXB) PROTEINS AND CONJUGATES THEREOF Institut Curie (FR) 2023-10-11 — — EP disclosed
EP-4185384-A1 CD38-BINDING CD31 PEPTIDES AND USES THEREOF ENCEFA (FR) 2023-05-31 — — EP disclosed
WO-2023041717-A1 ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF ABOLERIS PHARMA (FR) 2023-03-23 — — WO disclosed
US-20220233673-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2022-07-28 — — US disclosed
WO-2022117764-A1 FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF INSTITUT CURIE (FR) 2022-06-09 — — WO disclosed
EP-3980057-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF Institut Curie (FR) 2022-04-13 — — EP disclosed
EP-3807416-B1 METHOD FOR DETECTING BACTERIA ACCORDING TO THE GRAM SIGNAL THEREOF IN A COMPLEX SAMPLE MAAT PHARMA (FR) 2022-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240033366-A1 FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF STXBP1, STX18, SCTR CA2 4536/4885CA1 3993/4885CA9 4480/4885
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof STXBP1, RNGTT, UPF1 CA2 4557/4885CA1 4068/4885CA9 4739/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 CA2 4336/4885CA1 3497/4885CA9 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.